Stock Scorecard
Stock Summary for Rani Therapeutics Holdings Inc Class A (RANI) - $2.05 as of 11/20/2024 8:37:53 PM EST
Total Score
3 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for RANI
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RANI
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RANI
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for RANI
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for RANI (19 out of 90)
Stock Price Rating (Max of 10) | 3 |
Historical Stock Price Rating (Max of 10) | 1 |
Stock Price Trend (Max of 10) | 0 |
Book Value (Max of 10) | 1 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 5 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 5 |
Price to Earnings (Max of 10) | 0 |
Latest News for for RANI
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering 7/22/2024 12:30:00 PM |
Financial Details for RANI
Company Overview |
|
---|---|
Ticker | RANI |
Company Name | Rani Therapeutics Holdings Inc Class A |
Country | USA |
Description | N/A |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 2.05 |
Price 4 Years Ago | 0.00 |
Last Day Price Updated | 11/20/2024 8:37:53 PM EST |
Last Day Volume | 420,917 |
Average Daily Volume | 3,499,993 |
52-Week High | 8.75 |
52-Week Low | 1.90 |
Last Price to 52 Week Low | 7.89% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 22.60 |
Sector PE | 40.32 |
5-Year Average PE | -9.00 |
Free Cash Flow Ratio | 15.77 |
Industry Free Cash Flow Ratio | 12.03 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 1.60 |
Total Cash Per Share | 0.13 |
Book Value Per Share Most Recent Quarter | 0.49 |
Price to Book Ratio | 26.01 |
Industry Price to Book Ratio | 5.31 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 313.17 |
Industry Price to Sales Ratio Twelve Trailing Months | 11.82 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | 6 |
Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
Total Shares Outstanding | 33,311,500 |
Market Capitalization | 68,288,575 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -11.06% |
Reported EPS 12 Trailing Months | -1.07 |
Reported EPS Past Year | -0.79 |
Reported EPS Prior Year | -1.33 |
Net Income Twelve Trailing Months | -28,169,000 |
Net Income Past Year | -33,970,000 |
Net Income Prior Year | -30,588,000 |
Quarterly Revenue Growth YOY | -100.00% |
5-Year Revenue Growth | -52.81% |
Operating Margin Twelve Trailing Months | 0.00 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 4,277,000 |
Total Cash Past Year | 5,864,000 |
Total Cash Prior Year | 125,507,000 |
Net Cash Position Most Recent Quarter | -24,473,000 |
Net Cash Position Past Year | -24,136,000 |
Long Term Debt Past Year | 30,000,000 |
Long Term Debt Prior Year | 30,000,000 |
Total Debt Most Recent Quarter | 28,750,000 |
Equity to Debt Ratio Past Year | 0.30 |
Equity to Debt Ratio Most Recent Quarter | 0.10 |
Total Stockholder Equity Past Year | 12,866,000 |
Total Stockholder Equity Prior Year | 36,855,000 |
Total Stockholder Equity Most Recent Quarter | 3,120,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -39,723,000 |
Free Cash Flow Per Share Twelve Trailing Months | -1.19 |
Free Cash Flow Past Year | -52,465,000 |
Free Cash Flow Prior Year | -48,134,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.00 |
MACD Signal | -0.01 |
20-Day Bollinger Lower Band | 1.72 |
20-Day Bollinger Middle Band | 2.67 |
20-Day Bollinger Upper Band | 3.61 |
Beta | 0.11 |
RSI | 48.52 |
50-Day SMA | 3.59 |
150-Day SMA | 6.61 |
200-Day SMA | 0.00 |
System |
|
Modified | 11/19/2024 11:09:15 AM EST |